Advanced Filters
noise
Found 840 clinical trials

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.

55 - 90 years of age All Phase 2
P Pamela DeYoung, RPSGT

Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?

Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. We would like to examine how obstructive sleep apnea may contribute to …

65 - 85 years of age All Phase 1
M Marc VERNY, Pr

Social-cognitive Functioning: Validation of a New Neuropsychological Test

It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders. Their assessment is therefore essential, particularly in order to propose early and adapted care. However, this assessment remains limited today. A new serious game-type test, REALSoCog, …

18 - 90 years of age All Phase N/A
E Elsmarieke van de Giessen, MD

[18F]ACI-19626 PET in TDP-43 Proteinopathies

The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic lateral sclerosis (ALS)] using a new positron emission tomography (PET) tracer called [18F]ACI-19626. Both …

40 - 70 years of age All Phase N/A
Y Yan-Jiang Wang, MD, PhD

A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment \[MCI\] due to AD, or mild AD dementia). A total of 180 participants will be randomized into 3 parallel groups: 2 …

60 - 85 years of age All Phase 2

Treatment of Stress and Anxiety in MCI/Mild ADRD

The goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims …

60 years of age All Phase N/A
V Véronique ROCH, MSc

Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine

In Nuclear Medicine, the examinations are long (20-60 minutes) and the patients must remain immobile, sometimes fasting. The anxiety of the latter can lead to poor quality examinations and sometimes, although already injected with radioactive drugs, the patients refuse the examination. In imaging, the use of hypnosis (prior to the …

18 - 80 years of age All Phase N/A
L Linda Mah, MD, MHS, FRCPC

Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults

In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate Alzheimer's disease (AD) or mild cognitive impairment (MCI) and comorbid Major Depressive Disorder (MDD) who have …

60 years of age All Phase N/A
M Maggie Syme, PhD

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.

55 years of age All Phase N/A
S Sanjeev Kumar, MD, FRCPC

Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS

Agitation and aggression impose a tremendous burden on the individuals living with dementia, their families, caregivers, and healthcare systems. Neuropsychiatric symptoms of dementia (NPS) affect up to 80% of patients with Alzheimer's dementia (AD). The mechanisms of agitation in AD are poorly understood and the current interventions are only modestly …

50 years of age All Phase N/A

Simplify language using AI